Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

References

• Minuti G, D'Incecco A, Cappuzzo F. Targeted therapy for NSCLC with driver mutations. Expert Opin Biol Ther 2013;13:1401–12.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175–80.
   PubMed Web of Science ®Google Scholar
• Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121–7.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77.
   PubMed Web of Science ®Google Scholar
• Nassimi M, Schleh C, Lauenstein H, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 2010;75:107–16.
   PubMed Web of Science ®Google Scholar
• Nemati E, Azami A, Mokhtarzadeh A, et al. Formulation and characterization of ethambutol loaded nanostructured lipid carrier. Lat Am J Pharm 2017;36:247–52.
   Google Scholar
• Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bull 2015;5:151.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–96.
   PubMed Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Omidi Y. Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems. Trends Analyt Chem 2016;77:100–8.
   Web of Science ®Google Scholar
• Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. Google Patents 1993.
   Google Scholar
• Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2005;2:429–41.
   PubMedGoogle Scholar
• Barar J, Omidi Y, Gumbleton M. Molecular targeted therapy of lung cancer: challenges and promises. In: Martin G, Nokhodchi A, eds. Pulmonary drug delivery: advances and challenges. New York: John Wiley & Sons, Ltd.; 2016: 263–84.
   Google Scholar
• Dolatabadi JEN, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B 2014;117:21–8.
   PubMed Web of Science ®Google Scholar
• Eskandani M, Barar J, Ezzati Nazhad Dolatabadi J, et al. Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles. Pharm Biol 2015;53:1525–38.
   PubMed Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm 2015;41:1431–7.
   PubMed Web of Science ®Google Scholar
• Rahmanian N, Ezzati Nazhad Dolatabadi J, Omidi Y, et al. Preparation of dry powder inhaler of montelukast sodium- loaded solid lipid nanoparticles and evaluation of its physicochemical characteristics. Lat Am J Pharm 2016;35:853–61.
   Web of Science ®Google Scholar
• Arana L, Salado C, Vega S, et al. Solid lipid nanoparticles for delivery of Calendula officinalis extract. Colloids Surf B 2015;135:18–26.
   PubMed Web of Science ®Google Scholar
• Eskandani M, Hamishehkar H, Ezzati Nazhad Dolatabadi J. Cytotoxicity and DNA damage properties of tert-butylhydroquinone (TBHQ) food additive. Food Chem 2014;153:315–20.
   PubMed Web of Science ®Google Scholar
• Eskandani M, Hamishehkar H, Ezzati Nazhad Dolatabadi J. Cyto/genotoxicity study of polyoxyethylene (20) sorbitan monolaurate (Tween 20). DNA Cell Biol 2013;32:498–503.
   PubMed Web of Science ®Google Scholar
• Lee T, Hsu FB. A cross-performance relationship between Carr's index and dissolution rate constant: the study of acetaminophen batches. Drug Dev Ind Pharm 2007;33:1273–84.
   PubMed Web of Science ®Google Scholar
• Guo A, Beddow J, Vetter A. A simple relationship between particle shape effects and density, flow rate and Hausner ratio. Powder Technol 1985;43:279–84.
   Web of Science ®Google Scholar
• Hu L, Jia Y. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Die Pharmazie 2010;65:585–7.
   PubMed Web of Science ®Google Scholar
• Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356:333–44.
   PubMed Web of Science ®Google Scholar
• Xiang Q-y, Wang M-t, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007;30:519–25.
   PubMed Web of Science ®Google Scholar
• Esmaeili M, Aghajani M, Abbasalipourkabir R, Amani A. Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior. Artif Cells Nanomed Biotechnol 2016;44:1964–71.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller G. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227–34.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Ghaffari S, Mirshojaei S, et al. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. Biomed Res Int 2013;2013:136859.
   PubMed Web of Science ®Google Scholar
• Shah A, Bajaj AN, Jain DS. Fabrication and in vitro evaluation of solid lipid nanoparticles of mometasone furoate for pulmonary delivery. J Nanopharm Drug Deliv 2013;1:311–22.
   Google Scholar
• Li Y-Z, Sun X, Gong T, et al. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 2010;27:1977–86.
   PubMed Web of Science ®Google Scholar
• Paranjpe M, Finke J, Richter C, et al. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application. Int J Pharm 2014;476:41–9.
   PubMed Web of Science ®Google Scholar
• Al-Haj A, Ahmed N, Abdullah R, et al. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am J Pharmacol Toxicol 2008;3:219–24.
   Google Scholar
• Tang L, Yang X, Yin Q, et al. Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci USA 2014;111:15344–9.
   PubMed Web of Science ®Google Scholar
• Vidgren M, Kärkkäinen A, Karjalainen P, et al. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988;42:211–16.
   Web of Science ®Google Scholar
• I Ré M. Microencapsulation by spray drying. Drying Technol 1998;16:1195–236.
   Web of Science ®Google Scholar
• Zhao M, You Y, Ren Y, et al. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol 2008;187:214–21.
   Web of Science ®Google Scholar
• Kramek-Romanowska K, Odziomek M, Sosnowski TR, Gradon L. Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation. Ind Eng Chem Res 2011;50:13922–31.
   Web of Science ®Google Scholar
• Littringer EM, Noisternig MF, Mescher A, et al. The morphology and various densities of spray dried mannitol. Powder Technol 2013;246:193–200.
   Web of Science ®Google Scholar
• Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull 2012;2:183–7.
   PubMedGoogle Scholar
• Marple VA, Roberts DL, Romay FJ, et al. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design. J Aerosol Med 2003;16:283–99.
   PubMedGoogle Scholar
• Brown J, Cook K, Ney FG, Hatch T. Influence of particle size upon the retention of particulate matter in the human lung*†. Am J Public Health Nations Health 1950;40:450–80.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles. Int J Pharm 2012;424:98–106.
   PubMed Web of Science ®Google Scholar
• Deis RC, Kearsley MW. Sorbitol and mannitol. In: O'Donnell, K, Kearsley, M, eds. Sweeteners and sugar alternatives in food technology. Wiley-Blackwell; 2012:331–46.
   Google Scholar
• Videira MA, Botelho MF, Santos AC, et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002;10:607–13.
   Google Scholar